Skip to main content
Top
Published in: Neurology and Therapy 1/2021

Open Access 01-06-2021 | Multiple Sclerosis | Review

Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review

Authors: Lynsey Lakin, Bryan E. Davis, Cherie C. Binns, Keisha M. Currie, Mary R. Rensel

Published in: Neurology and Therapy | Issue 1/2021

Login to get access

Abstract

Multiple sclerosis (MS) is a chronic autoimmune inflammatory disease of the central nervous system, leading to neurodegeneration and manifesting as a variety of symptoms. These can include “invisible” symptoms, not externally evident to others, such as fatigue, mood disorders, cognitive impairments, pain, bladder/bowel dysfunction, sexual dysfunction, and vision changes. Invisible symptoms are highly prevalent in people living with MS, with multifactorial etiology and potential to impact the disease course. Patient experiences of these symptoms include both physical and psychosocial elements, which when unaddressed negatively influence many aspects of quality of life and perception of health. Despite the high impact on patient lives, gaps persist in awareness and management of these hidden symptoms. The healthcare provider and patient author experiences brought together here serve to raise the profile of invisible symptoms and review strategies for a team-based approach to comprehensive MS care. We summarize the current literature regarding the prevalence and etiology of invisible symptoms to convey the high likelihood that a person living with MS will contend with one or more of these concerns. We then explore how open communication between people living with MS and their care team, stigma mitigation, and shared decision-making are key to comprehensive management of invisible symptoms. We recommend validated screening tools and technological advancements that may be incorporated into MS care to regularly monitor these symptoms, offering insight into how healthcare providers can both educate and listen to patients, with the goal of improved patient quality of life. By pairing clinical knowledge with an understanding and consideration of the patient perspective, providers will be equipped to foster a patient-centered dialogue that encourages shared decision-making.
Invisible symptoms of MS

Graphical Plain Language Summary

Literature
2.
go back to reference White CP, White MB, Russell CS. Invisible and visible symptoms of multiple sclerosis: which are more predictive of health distress? J Neurosci Nurs. 2008;40(2):85–95 (102).PubMed White CP, White MB, Russell CS. Invisible and visible symptoms of multiple sclerosis: which are more predictive of health distress? J Neurosci Nurs. 2008;40(2):85–95 (102).PubMed
4.
go back to reference Green R, Cutter G, Friendly M, Kister I. Which symptoms contribute the most to patients’ perception of health in multiple sclerosis? Mult Scler J Exp Transl Clin. 2017;3(3):2055217317728301.PubMedPubMedCentral Green R, Cutter G, Friendly M, Kister I. Which symptoms contribute the most to patients’ perception of health in multiple sclerosis? Mult Scler J Exp Transl Clin. 2017;3(3):2055217317728301.PubMedPubMedCentral
5.
go back to reference Yalachkov Y, Soydas D, Bergmann J, Frisch S, Behrens M, Foerch C, et al. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30:33–7.PubMed Yalachkov Y, Soydas D, Bergmann J, Frisch S, Behrens M, Foerch C, et al. Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;30:33–7.PubMed
7.
go back to reference Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205(1):51–8.PubMed Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci. 2002;205(1):51–8.PubMed
8.
go back to reference Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–6.PubMed Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692–6.PubMed
9.
go back to reference Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain. 1994;58(1):89–93.PubMed Archibald CJ, McGrath PJ, Ritvo PG, Fisk JD, Bhan V, Maxner CE, et al. Pain prevalence, severity and impact in a clinic sample of multiple sclerosis patients. Pain. 1994;58(1):89–93.PubMed
10.
go back to reference Kalia LV, O’Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. 2005;11(3):322–7.PubMed Kalia LV, O’Connor PW. Severity of chronic pain and its relationship to quality of life in multiple sclerosis. Mult Scler. 2005;11(3):322–7.PubMed
11.
go back to reference Vitkova M, Rosenberger J, Krokavcova M, Szilasiova J, Gdovinova Z, Groothoff JW, et al. Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction. Disabil Rehabil. 2014;36(12):987–92.PubMed Vitkova M, Rosenberger J, Krokavcova M, Szilasiova J, Gdovinova Z, Groothoff JW, et al. Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction. Disabil Rehabil. 2014;36(12):987–92.PubMed
12.
go back to reference McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90(15):e1316–23.PubMedPubMedCentral McKay KA, Tremlett H, Fisk JD, Zhang T, Patten SB, Kastrukoff L, et al. Psychiatric comorbidity is associated with disability progression in multiple sclerosis. Neurology. 2018;90(15):e1316–23.PubMedPubMedCentral
13.
go back to reference Mowry EM, Bermel RA, Williams JR, Benzinger TLS, de Moor C, Fisher E, et al. Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Front Neurol. 2020;11:632.PubMedPubMedCentral Mowry EM, Bermel RA, Williams JR, Benzinger TLS, de Moor C, Fisher E, et al. Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Front Neurol. 2020;11:632.PubMedPubMedCentral
14.
go back to reference Baldassari LE, Nakamura K, Moss BP, Macaron G, Li H, Weber M, et al. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Mult Scler Relat Disord. 2020;38:101525.PubMed Baldassari LE, Nakamura K, Moss BP, Macaron G, Li H, Weber M, et al. Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Mult Scler Relat Disord. 2020;38:101525.PubMed
15.
go back to reference Rae-Grant A, Bennett A, Sanders AE, Phipps M, Cheng E, Bever C. Quality improvement in neurology: multiple sclerosis quality measures. Exec Summ. 2015;85(21):1904–8. Rae-Grant A, Bennett A, Sanders AE, Phipps M, Cheng E, Bever C. Quality improvement in neurology: multiple sclerosis quality measures. Exec Summ. 2015;85(21):1904–8.
16.
go back to reference Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5):S139–45.PubMed Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5):S139–45.PubMed
18.
go back to reference Kratz AL, Murphy SL, Braley TJ, Basu N, Kulkarni S, Russell J, et al. Development of a person-centered conceptual model of perceived fatigability. Qual Life Res. 2019;28(5):1337–47.PubMedPubMedCentral Kratz AL, Murphy SL, Braley TJ, Basu N, Kulkarni S, Russell J, et al. Development of a person-centered conceptual model of perceived fatigability. Qual Life Res. 2019;28(5):1337–47.PubMedPubMedCentral
19.
go back to reference Gullo HL, Fleming J, Bennett S, Shum DHK. Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis. Mult Scler Relat Disord. 2019;31:118–23.PubMed Gullo HL, Fleming J, Bennett S, Shum DHK. Cognitive and physical fatigue are associated with distinct problems in daily functioning, role fulfilment, and quality of life in multiple sclerosis. Mult Scler Relat Disord. 2019;31:118–23.PubMed
20.
go back to reference Brass SD, Li CS, Auerbach S. The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med. 2014;10(9):1025–31.PubMedPubMedCentral Brass SD, Li CS, Auerbach S. The underdiagnosis of sleep disorders in patients with multiple sclerosis. J Clin Sleep Med. 2014;10(9):1025–31.PubMedPubMedCentral
21.
go back to reference Veauthier C. Sleep disorders in multiple sclerosis. Rev Curr Neurol Neurosci Rep. 2015;15(5):21. Veauthier C. Sleep disorders in multiple sclerosis. Rev Curr Neurol Neurosci Rep. 2015;15(5):21.
22.
go back to reference Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verhey FR. The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res. 2009;66(1):3–11.PubMed Bol Y, Duits AA, Hupperts RM, Vlaeyen JW, Verhey FR. The psychology of fatigue in patients with multiple sclerosis: a review. J Psychosom Res. 2009;66(1):3–11.PubMed
23.
go back to reference Ford H, Trigwell P, Johnson M. The nature of fatigue in multiple sclerosis. J Psychosom Res. 1998;45(1):33–8.PubMed Ford H, Trigwell P, Johnson M. The nature of fatigue in multiple sclerosis. J Psychosom Res. 1998;45(1):33–8.PubMed
24.
go back to reference Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. 2010;10(9):1437–47.PubMed Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. 2010;10(9):1437–47.PubMed
25.
go back to reference Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–17.PubMed Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol. 2014;10(9):507–17.PubMed
27.
go back to reference Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41.PubMed Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41.PubMed
29.
go back to reference Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73(6):411–7.PubMed Pompili M, Forte A, Palermo M, Stefani H, Lamis DA, Serafini G, et al. Suicide risk in multiple sclerosis: a systematic review of current literature. J Psychosom Res. 2012;73(6):411–7.PubMed
30.
go back to reference Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674–8.PubMed Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology. 2002;59(5):674–8.PubMed
31.
go back to reference Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14–21.PubMed Paparrigopoulos T, Ferentinos P, Kouzoupis A, Koutsis G, Papadimitriou GN. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14–21.PubMed
32.
go back to reference Brenner P, Burkill S, Jokinen J, Hillert J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide—a cohort study. Eur J Neurol. 2016;23(8):1329–36.PubMed Brenner P, Burkill S, Jokinen J, Hillert J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide—a cohort study. Eur J Neurol. 2016;23(8):1329–36.PubMed
33.
go back to reference Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017;23(7):923–7.PubMed Feinstein A, Pavisian B. Multiple sclerosis and suicide. Mult Scler. 2017;23(7):923–7.PubMed
34.
go back to reference Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA. Pseudobulbar affect. Prev Assoc Symptoms Multi Scler. 2018;8(6):472–81. Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Marrie RA. Pseudobulbar affect. Prev Assoc Symptoms Multi Scler. 2018;8(6):472–81.
35.
go back to reference Work SS, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther. 2011;28(7):586–601.PubMed Work SS, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Adv Ther. 2011;28(7):586–601.PubMed
37.
go back to reference Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.PubMed Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139–51.PubMed
38.
go back to reference Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278–88.PubMedPubMedCentral Sumowski JF, Benedict R, Enzinger C, Filippi M, Geurts JJ, Hamalainen P, et al. Cognition in multiple sclerosis: state of the field and priorities for the future. Neurology. 2018;90(6):278–88.PubMedPubMedCentral
39.
go back to reference Trenova AG, Slavov GS, Manova MG, Aksentieva JB, Miteva LD, Stanilova SA. Cognitive impairment in multiple sclerosis. Folia Med (Plovdiv). 2016;58(3):157–63. Trenova AG, Slavov GS, Manova MG, Aksentieva JB, Miteva LD, Stanilova SA. Cognitive impairment in multiple sclerosis. Folia Med (Plovdiv). 2016;58(3):157–63.
40.
go back to reference Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E, et al. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE. 2013;8(8):e71058.PubMedPubMedCentral Achiron A, Chapman J, Magalashvili D, Dolev M, Lavie M, Bercovich E, et al. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS ONE. 2013;8(8):e71058.PubMedPubMedCentral
41.
go back to reference Achiron A, Barak Y. Cognitive changes in early MS: a call for a common framework. J Neurol Sci. 2006;245(1–2):47–51.PubMed Achiron A, Barak Y. Cognitive changes in early MS: a call for a common framework. J Neurol Sci. 2006;245(1–2):47–51.PubMed
42.
go back to reference Schulz D, Kopp B, Kunkel A, Faiss JH. Cognition in the early stage of multiple sclerosis. J Neurol. 2006;253(8):1002–10.PubMed Schulz D, Kopp B, Kunkel A, Faiss JH. Cognition in the early stage of multiple sclerosis. J Neurol. 2006;253(8):1002–10.PubMed
43.
44.
go back to reference Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, et al. Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behav Neurol. 2017;2017:7404289.PubMedPubMedCentral Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, et al. Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behav Neurol. 2017;2017:7404289.PubMedPubMedCentral
45.
go back to reference Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, et al. Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology. 2019;92(5):e406–17.PubMedCentral Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, et al. Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology. 2019;92(5):e406–17.PubMedCentral
46.
go back to reference Clemens L, Langdon D. How does cognition relate to employment in multiple sclerosis? A systematic review. Mult Scler Relat Disord. 2018;26:183–91.PubMed Clemens L, Langdon D. How does cognition relate to employment in multiple sclerosis? A systematic review. Mult Scler Relat Disord. 2018;26:183–91.PubMed
47.
go back to reference Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685–91.PubMed Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology. 1991;41(5):685–91.PubMed
48.
go back to reference Kordovski VM, Frndak SE, Fisher CS, Rodgers J, Weinstock-Guttman B, Benedict RHB. Identifying employed multiple sclerosis patients at-risk for job loss: when do negative work events pose a threat? Multi Scler Relat Disord. 2015;4(5):409–13. Kordovski VM, Frndak SE, Fisher CS, Rodgers J, Weinstock-Guttman B, Benedict RHB. Identifying employed multiple sclerosis patients at-risk for job loss: when do negative work events pose a threat? Multi Scler Relat Disord. 2015;4(5):409–13.
49.
go back to reference McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J. Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis. JAMA Neurol. 2019;76(9):1028–34.PubMedPubMedCentral McKay KA, Manouchehrinia A, Berrigan L, Fisk JD, Olsson T, Hillert J. Long-term cognitive outcomes in patients with pediatric-onset vs adult-onset multiple sclerosis. JAMA Neurol. 2019;76(9):1028–34.PubMedPubMedCentral
50.
go back to reference Parrish JB, Fields E. Cognitive functioning in patients with pediatric-onset multiple sclerosis, an updated review and future focus. Children (Basel). 2019;6(2):21. Parrish JB, Fields E. Cognitive functioning in patients with pediatric-onset multiple sclerosis, an updated review and future focus. Children (Basel). 2019;6(2):21.
51.
go back to reference Kahraman T, Ozdogar AT, Ertekin O, Ozakbas S. Frequency, type, distribution of pain and related factors in persons with multiple sclerosis(). Mult Scler Relat Disord. 2019;28:221–5.PubMed Kahraman T, Ozdogar AT, Ertekin O, Ozakbas S. Frequency, type, distribution of pain and related factors in persons with multiple sclerosis(). Mult Scler Relat Disord. 2019;28:221–5.PubMed
52.
go back to reference Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154(5):632–42.PubMed Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154(5):632–42.PubMed
53.
go back to reference Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol. 1984;41(12):1270–2.PubMed Clifford DB, Trotter JL. Pain in multiple sclerosis. Arch Neurol. 1984;41(12):1270–2.PubMed
54.
go back to reference Solaro C, Trabucco E, Messmer UM. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.PubMed Solaro C, Trabucco E, Messmer UM. Pain and multiple sclerosis: pathophysiology and treatment. Curr Neurol Neurosci Rep. 2013;13(1):320.PubMed
55.
go back to reference Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci. 1995;16(9):629–32.PubMed Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. Ital J Neurol Sci. 1995;16(9):629–32.PubMed
57.
go back to reference Mazhari A. Multiple sclerosis-related pain syndromes: an imaging update. Curr Pain Headache Rep. 2016;20(12):63.PubMed Mazhari A. Multiple sclerosis-related pain syndromes: an imaging update. Curr Pain Headache Rep. 2016;20(12):63.PubMed
58.
go back to reference Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology. 2017;88(16):1528–34.PubMed Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ. High hypothetical interest in physician-assisted death in multiple sclerosis. Neurology. 2017;88(16):1528–34.PubMed
59.
go back to reference Collongues N, Vermersch P. Multiple sclerosis spasticity: “state-of-the-art” questionnaire survey of specialized healthcare professionals. Expert Rev Neurother. 2013;13(3 Suppl 1):21–5.PubMed Collongues N, Vermersch P. Multiple sclerosis spasticity: “state-of-the-art” questionnaire survey of specialized healthcare professionals. Expert Rev Neurother. 2013;13(3 Suppl 1):21–5.PubMed
60.
go back to reference Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain Behav. 2015;5(9):e00367.PubMedPubMedCentral Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain Behav. 2015;5(9):e00367.PubMedPubMedCentral
63.
go back to reference Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003;82(3):327–38.PubMed Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003;82(3):327–38.PubMed
64.
go back to reference Browne C, Salmon N, Kehoe M. Bladder dysfunction and quality of life for people with multiple sclerosis. Disabil Rehabil. 2015;37(25):2350–8.PubMed Browne C, Salmon N, Kehoe M. Bladder dysfunction and quality of life for people with multiple sclerosis. Disabil Rehabil. 2015;37(25):2350–8.PubMed
65.
go back to reference Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018;8:79–90.PubMedPubMedCentral Preziosi G, Gordon-Dixon A, Emmanuel A. Neurogenic bowel dysfunction in patients with multiple sclerosis: prevalence, impact, and management strategies. Degener Neurol Neuromuscul Dis. 2018;8:79–90.PubMedPubMedCentral
67.
go back to reference Norton C, Chelvanayagam S. Bowel problems and coping strategies in people with multiple sclerosis. Br J Nurs. 2010;19(4):220 (1-6).PubMed Norton C, Chelvanayagam S. Bowel problems and coping strategies in people with multiple sclerosis. Br J Nurs. 2010;19(4):220 (1-6).PubMed
68.
go back to reference Dibley L, Coggrave M, McClurg D, Woodward S, Norton C. “It’s just horrible”: a qualitative study of patients’ and carers’ experiences of bowel dysfunction in multiple sclerosis. J Neurol. 2017;264(7):1354–61.PubMed Dibley L, Coggrave M, McClurg D, Woodward S, Norton C. “It’s just horrible”: a qualitative study of patients’ and carers’ experiences of bowel dysfunction in multiple sclerosis. J Neurol. 2017;264(7):1354–61.PubMed
69.
go back to reference Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:319201.PubMedPubMedCentral Levinthal DJ, Rahman A, Nusrat S, O’Leary M, Heyman R, Bielefeldt K. Adding to the burden: gastrointestinal symptoms and syndromes in multiple sclerosis. Mult Scler Int. 2013;2013:319201.PubMedPubMedCentral
70.
go back to reference Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A. Functional gastrointestinal disorders negatively affect health-related quality of life in MS. Neurol Clin Pract. 2019;9(5):381–90.PubMedPubMedCentral Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A. Functional gastrointestinal disorders negatively affect health-related quality of life in MS. Neurol Clin Pract. 2019;9(5):381–90.PubMedPubMedCentral
72.
go back to reference Domingo S, Kinzy T, Thompson N, Gales S, Stone L, Sullivan A. Factors associated with sexual dysfunction in individuals with multiple sclerosis: implications for assessment and treatment. Int J MS Care. 2018;20(4):191–7.PubMedPubMedCentral Domingo S, Kinzy T, Thompson N, Gales S, Stone L, Sullivan A. Factors associated with sexual dysfunction in individuals with multiple sclerosis: implications for assessment and treatment. Int J MS Care. 2018;20(4):191–7.PubMedPubMedCentral
74.
75.
go back to reference Schmidt EZ, Hofmann P, Niederwieser G, Kapfhammer HP, Bonelli RM. Sexuality in multiple sclerosis. J Neural Transm (Vienna). 2005;112(9):1201–11. Schmidt EZ, Hofmann P, Niederwieser G, Kapfhammer HP, Bonelli RM. Sexuality in multiple sclerosis. J Neural Transm (Vienna). 2005;112(9):1201–11.
76.
go back to reference Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96–107.PubMed Fletcher SG, Castro-Borrero W, Remington G, Treadaway K, Lemack GE, Frohman EM. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96–107.PubMed
78.
go back to reference Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Multi Scler J. 2006;12(2):209–11. Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Multi Scler J. 2006;12(2):209–11.
79.
go back to reference Bronner G, Elran E, Golomb J, Korczyn AD. Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. Acta Neurol Scand. 2010;121(5):289–301.PubMed Bronner G, Elran E, Golomb J, Korczyn AD. Female sexuality in multiple sclerosis: the multidimensional nature of the problem and the intervention. Acta Neurol Scand. 2010;121(5):289–301.PubMed
80.
go back to reference Çelik DB, Poyraz EÇ, Bingöl A, İdiman E, Özakbaş S, Kaya D. Sexual dysfunction in multiple sclerosis: gender differences. J Neurol Sci. 2013;324(1):17–20.PubMed Çelik DB, Poyraz EÇ, Bingöl A, İdiman E, Özakbaş S, Kaya D. Sexual dysfunction in multiple sclerosis: gender differences. J Neurol Sci. 2013;324(1):17–20.PubMed
81.
go back to reference Borello-France D, Leng W, O’Leary M, Xavier M, Erickson J, Chancellor MB, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler. 2004;10(4):455–61.PubMed Borello-France D, Leng W, O’Leary M, Xavier M, Erickson J, Chancellor MB, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler. 2004;10(4):455–61.PubMed
82.
go back to reference Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009;9(3):341–50.PubMed Kessler TM, Fowler CJ, Panicker JN. Sexual dysfunction in multiple sclerosis. Expert Rev Neurother. 2009;9(3):341–50.PubMed
84.
go back to reference Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain J Neurol. 2015;138(Pt 1):11–27. Balcer LJ, Miller DH, Reingold SC, Cohen JA. Vision and vision-related outcome measures in multiple sclerosis. Brain J Neurol. 2015;138(Pt 1):11–27.
85.
go back to reference Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. “Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler. 2013;19(7):953–60.PubMed Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. “Seeing” in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler. 2013;19(7):953–60.PubMed
87.
go back to reference Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80(7):767–72.PubMed Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80(7):767–72.PubMed
88.
go back to reference Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2011;31(4):362–73.PubMedPubMedCentral Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2011;31(4):362–73.PubMedPubMedCentral
89.
go back to reference Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008;22(1):91–100.PubMed Kos D, Kerckhofs E, Nagels G, D’Hooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair. 2008;22(1):91–100.PubMed
90.
go back to reference Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–7.PubMedPubMedCentral Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061–7.PubMedPubMedCentral
91.
go back to reference Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004;328(7442):731.PubMedPubMedCentral Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis. BMJ. 2004;328(7442):731.PubMedPubMedCentral
92.
go back to reference Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012;79(5):412–9.PubMedPubMedCentral Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, et al. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012;79(5):412–9.PubMedPubMedCentral
93.
go back to reference Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology. 2011;36(2):109–20.PubMed Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology. 2011;36(2):109–20.PubMed
95.
go back to reference Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016;139(Pt 1):115–26.PubMed Steenwijk MD, Geurts JJ, Daams M, Tijms BM, Wink AM, Balk LJ, et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. Brain. 2016;139(Pt 1):115–26.PubMed
96.
go back to reference Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–67.PubMed Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–67.PubMed
97.
go back to reference Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860–71.PubMed Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19(10):860–71.PubMed
98.
go back to reference Sander C, Eling P, Hanken K, Klein J, Kastrup A, Hildebrandt H. The Impact of MS-Related Cognitive Fatigue on Future Brain Parenchymal Loss and Relapse: A 17-Month Follow-up Study. Front Neurol. 2016;7:155.PubMedPubMedCentral Sander C, Eling P, Hanken K, Klein J, Kastrup A, Hildebrandt H. The Impact of MS-Related Cognitive Fatigue on Future Brain Parenchymal Loss and Relapse: A 17-Month Follow-up Study. Front Neurol. 2016;7:155.PubMedPubMedCentral
99.
go back to reference Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(6):642–51.PubMed Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, et al. Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(6):642–51.PubMed
100.
go back to reference Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmun Highlights. 2019;10(1):7. Andravizou A, Dardiotis E, Artemiadis A, Sokratous M, Siokas V, Tsouris Z, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmun Highlights. 2019;10(1):7.
101.
go back to reference Bove R, Chitnis T, Houtchens M. Menopause in multiple sclerosis: therapeutic considerations. J Neurol. 2014;261(7):1257–68.PubMed Bove R, Chitnis T, Houtchens M. Menopause in multiple sclerosis: therapeutic considerations. J Neurol. 2014;261(7):1257–68.PubMed
102.
go back to reference Dorstyn DS, Mathias JL, Bombardier CH, Osborn AJ. Motivational interviewing to promote health outcomes and behaviour change in multiple sclerosis: a systematic review. Clin Rehabil. 2020;34(3):299–309.PubMed Dorstyn DS, Mathias JL, Bombardier CH, Osborn AJ. Motivational interviewing to promote health outcomes and behaviour change in multiple sclerosis: a systematic review. Clin Rehabil. 2020;34(3):299–309.PubMed
103.
go back to reference Rosengren DB. Building motivational interviewing skills: a practitioner workbook. Rollnick S, Miller WR, editors. New York, NY: The Guilford Press; 2009. Rosengren DB. Building motivational interviewing skills: a practitioner workbook. Rollnick S, Miller WR, editors. New York, NY: The Guilford Press; 2009.
106.
go back to reference Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of “no evidence of disease activity” in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8(1):3–13.PubMedPubMedCentral Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of “no evidence of disease activity” in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8(1):3–13.PubMedPubMedCentral
107.
go back to reference Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4.PubMedPubMedCentral Brazier JE, Harper R, Jones NM, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ. 1992;305(6846):160–4.PubMedPubMedCentral
108.
go back to reference Krokavcova M, van Dijk JP, Nagyova I, Rosenberger J, Gavelova M, Gdovinova Z, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review. Scand J Caring Sci. 2009;23(3):529–38.PubMed Krokavcova M, van Dijk JP, Nagyova I, Rosenberger J, Gavelova M, Gdovinova Z, et al. Perceived health status as measured by the SF-36 in patients with multiple sclerosis: a review. Scand J Caring Sci. 2009;23(3):529–38.PubMed
111.
go back to reference Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21(3):475–86.PubMed Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, et al. Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res. 2012;21(3):475–86.PubMed
113.
go back to reference Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, et al. Multiple sclerosis performance test: technical development and usability. Adv Ther. 2019;36(7):1741–55.PubMedPubMedCentral Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, et al. Multiple sclerosis performance test: technical development and usability. Adv Ther. 2019;36(7):1741–55.PubMedPubMedCentral
114.
go back to reference Rao SM, Galioto R, Sokolowski M, McGinley M, Freiburger J, Weber M, et al. Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules. Eur J Neurol. 2020;27(5):878–86.PubMed Rao SM, Galioto R, Sokolowski M, McGinley M, Freiburger J, Weber M, et al. Multiple Sclerosis Performance Test: validation of self-administered neuroperformance modules. Eur J Neurol. 2020;27(5):878–86.PubMed
115.
go back to reference Macaron G, Moss BP, Li H, Baldassari LE, Rao SM, Schindler D, et al. Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurol Clin Pract. 2020;10(3):222–31.PubMedPubMedCentral Macaron G, Moss BP, Li H, Baldassari LE, Rao SM, Schindler D, et al. Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurol Clin Pract. 2020;10(3):222–31.PubMedPubMedCentral
117.
go back to reference Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.PubMed Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.PubMed
118.
go back to reference Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540–5.PubMed Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14(6):540–5.PubMed
119.
go back to reference Popp RF, Fierlbeck AK, Knüttel H, König N, Rupprecht R, Weissert R, et al. Daytime sleepiness versus fatigue in patients with multiple sclerosis: a systematic review on the Epworth sleepiness scale as an assessment tool. Sleep Med Rev. 2017;32:95–108.PubMed Popp RF, Fierlbeck AK, Knüttel H, König N, Rupprecht R, Weissert R, et al. Daytime sleepiness versus fatigue in patients with multiple sclerosis: a systematic review on the Epworth sleepiness scale as an assessment tool. Sleep Med Rev. 2017;32:95–108.PubMed
120.
go back to reference Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21(1):9–14.PubMed Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21(1):9–14.PubMed
121.
go back to reference Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79-83.PubMed Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79-83.PubMed
123.
go back to reference Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 1995;45(4):718–23.PubMed Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR, Goodkin DE. Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). Neurology. 1995;45(4):718–23.PubMed
124.
go back to reference Kaya F, Delen E, Bulut O. Test review: shipley-2 manual. J Psychoeduc Assess. 2012;30(6):593–7. Kaya F, Delen E, Bulut O. Test review: shipley-2 manual. J Psychoeduc Assess. 2012;30(6):593–7.
125.
go back to reference Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721–33.PubMedPubMedCentral Benedict RH, DeLuca J, Phillips G, LaRocca N, Hudson LD, Rudick R. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler. 2017;23(5):721–33.PubMedPubMedCentral
126.
go back to reference Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test, second edition (CVLT-II). Psychological Corporation; 2000. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test, second edition (CVLT-II). Psychological Corporation; 2000.
127.
go back to reference Stegen S, Stepanov I, Cookfair D, Schwartz E, Hojnacki D, Weinstock-Guttman B, et al. Validity of the California verbal learning test-II in multiple sclerosis. Clin Neuropsychol. 2010;24(2):189–202.PubMed Stegen S, Stepanov I, Cookfair D, Schwartz E, Hojnacki D, Weinstock-Guttman B, et al. Validity of the California verbal learning test-II in multiple sclerosis. Clin Neuropsychol. 2010;24(2):189–202.PubMed
129.
go back to reference Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018;24(13):1665–80.PubMedPubMedCentral Kalb R, Beier M, Benedict RH, Charvet L, Costello K, Feinstein A, et al. Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler. 2018;24(13):1665–80.PubMedPubMedCentral
130.
go back to reference Chibnall JT, Tait RC. The Pain Disability Index: factor structure and normative data. Arch Phys Med Rehabil. 1994;75(10):1082–6.PubMed Chibnall JT, Tait RC. The Pain Disability Index: factor structure and normative data. Arch Phys Med Rehabil. 1994;75(10):1082–6.PubMed
131.
go back to reference Villoslada P, Sanchez-Dalmau B, Galetta S. Optical coherence tomography: a useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology. 2020;95(6):239–40.PubMed Villoslada P, Sanchez-Dalmau B, Galetta S. Optical coherence tomography: a useful tool for identifying subclinical optic neuropathy in diagnosing multiple sclerosis. Neurology. 2020;95(6):239–40.PubMed
132.
go back to reference Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.PubMedPubMedCentral Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.PubMedPubMedCentral
133.
go back to reference Terrill AL, Hartoonian N, Beier M, Salem R, Alschuler KN. The 7-item generalized anxiety disorder scale as a tool for measuring generalized anxiety in multiple sclerosis. Int J MS care. 2015;17(2):49–56.PubMedPubMedCentral Terrill AL, Hartoonian N, Beier M, Salem R, Alschuler KN. The 7-item generalized anxiety disorder scale as a tool for measuring generalized anxiety in multiple sclerosis. Int J MS care. 2015;17(2):49–56.PubMedPubMedCentral
134.
go back to reference Beck AT, Steer RA, Brown G. Manual for the beck depression inventory-II. Psychological Corporation; 1996. Beck AT, Steer RA, Brown G. Manual for the beck depression inventory-II. Psychological Corporation; 1996.
135.
go back to reference National MS Society. But you look so good! In: Society NM, editor. Internet2016. National MS Society. But you look so good! In: Society NM, editor. Internet2016.
136.
go back to reference Cadden MH, Arnett PA, Tyry TM, Cook JE. Judgment hurts: The psychological consequences of experiencing stigma in multiple sclerosis. Soc Sci Med. 2018;208:158–64.PubMed Cadden MH, Arnett PA, Tyry TM, Cook JE. Judgment hurts: The psychological consequences of experiencing stigma in multiple sclerosis. Soc Sci Med. 2018;208:158–64.PubMed
137.
go back to reference McBurney RN, Zhao Y, Loud S, Balasubramanian R, Schmidt H, Kolaczkowski L, editors. Factors correlating with patient-reported measurements of stigma and satisfaction with social roles and activities reported by the iConquerMS Network. In: CMSC; 2017. McBurney RN, Zhao Y, Loud S, Balasubramanian R, Schmidt H, Kolaczkowski L, editors. Factors correlating with patient-reported measurements of stigma and satisfaction with social roles and activities reported by the iConquerMS Network. In: CMSC; 2017.
138.
go back to reference Grytten N, Måseide P. “What is expressed is not always what is felt”: coping with stigma and the embodiment of perceived illegitimacy of multiple sclerosis. Chronic Illn. 2005;1(3):231–43.PubMed Grytten N, Måseide P. “What is expressed is not always what is felt”: coping with stigma and the embodiment of perceived illegitimacy of multiple sclerosis. Chronic Illn. 2005;1(3):231–43.PubMed
139.
go back to reference Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E. The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work. 2018;60(2):263–70.PubMed Lorefice L, Fenu G, Frau J, Coghe G, Marrosu MG, Cocco E. The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. Work. 2018;60(2):263–70.PubMed
140.
go back to reference Kahraman T, Ozdogar AT, Honan CA, Ertekin O, Ozakbas S. The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability. Disabil Rehabil. 2019;41(21):2556–62.PubMed Kahraman T, Ozdogar AT, Honan CA, Ertekin O, Ozakbas S. The multiple sclerosis work difficulties questionnaire: translation and cross-cultural adaptation to Turkish and assessment of validity and reliability. Disabil Rehabil. 2019;41(21):2556–62.PubMed
141.
go back to reference Krause JS, Dismuke-Greer CE, Jarnecke M, Li C, Reed KS, Rumrill P. Employment and gainful earnings among those with multiple sclerosis. Arch Phys Med Rehabil. 2019;100(5):931–7.PubMed Krause JS, Dismuke-Greer CE, Jarnecke M, Li C, Reed KS, Rumrill P. Employment and gainful earnings among those with multiple sclerosis. Arch Phys Med Rehabil. 2019;100(5):931–7.PubMed
142.
go back to reference Maurino J, Martínez-Ginés ML, García-Domínguez JM, Solar MD, Carcelén-Gadea M, Ares-Luque A, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis. Mult Scler Relat Disord. 2020;41:102046.PubMed Maurino J, Martínez-Ginés ML, García-Domínguez JM, Solar MD, Carcelén-Gadea M, Ares-Luque A, et al. Workplace difficulties, health-related quality of life, and perception of stigma from the perspective of patients with multiple sclerosis. Mult Scler Relat Disord. 2020;41:102046.PubMed
143.
go back to reference Grytten N, Måseide P. “When I am together with them I feel more ill.” The stigma of multiple sclerosis experienced in social relationships. Chronic Illn. 2006;2(3):195–208.PubMed Grytten N, Måseide P. “When I am together with them I feel more ill.” The stigma of multiple sclerosis experienced in social relationships. Chronic Illn. 2006;2(3):195–208.PubMed
144.
go back to reference Bolin E. Alone with MS: the symptom people don't talk about. MS FOCUS Mag. 2012. Bolin E. Alone with MS: the symptom people don't talk about. MS FOCUS Mag. 2012.
148.
go back to reference Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132–42.PubMedPubMedCentral Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM. Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract. 2015;5(2):132–42.PubMedPubMedCentral
149.
go back to reference Courtney SW, Amezcua L, Bernard J, Hancock L. Disease Effects and Needs of Minority Populations with MS. The Motivator. 2017. Courtney SW, Amezcua L, Bernard J, Hancock L. Disease Effects and Needs of Minority Populations with MS. The Motivator. 2017.
150.
go back to reference Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Multi Scl J. 2017;23(2):185–90. Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Multi Scl J. 2017;23(2):185–90.
151.
go back to reference Glass KE, Wills CE, Holloman C, Olson J, Hechmer C, Miller CK, et al. Shared decision making and other variables as correlates of satisfaction with health care decisions in a United States national survey. Patient Educ Couns. 2012;88(1):100–5.PubMedPubMedCentral Glass KE, Wills CE, Holloman C, Olson J, Hechmer C, Miller CK, et al. Shared decision making and other variables as correlates of satisfaction with health care decisions in a United States national survey. Patient Educ Couns. 2012;88(1):100–5.PubMedPubMedCentral
152.
go back to reference Tintoré M, Alexander M, Costello K, Duddy M, Jones DE, Law N, et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adher. 2017;11:33–45. Tintoré M, Alexander M, Costello K, Duddy M, Jones DE, Law N, et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adher. 2017;11:33–45.
153.
go back to reference Ross AP. Shared decision-making in multiple sclerosis management. Pract Neurol. 2017. Ross AP. Shared decision-making in multiple sclerosis management. Pract Neurol. 2017.
154.
go back to reference Tobin WO. Management of multiple sclerosis symptoms and comorbidities. Continuum (Minneap Minn). 2019;25(3):753–72. Tobin WO. Management of multiple sclerosis symptoms and comorbidities. Continuum (Minneap Minn). 2019;25(3):753–72.
155.
go back to reference Crabtree-Hartman E. advanced symptom management in multiple sclerosis. Neurol Clin. 2018;36(1):197–218.PubMed Crabtree-Hartman E. advanced symptom management in multiple sclerosis. Neurol Clin. 2018;36(1):197–218.PubMed
156.
go back to reference Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report Guideline Dev Subcommittee of the Am Acad Neurol. 2014;82(12):1083–92. Yadav V, Bever C, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis. Report Guideline Dev Subcommittee of the Am Acad Neurol. 2014;82(12):1083–92.
158.
go back to reference Penner I. editor Treatment of cognitive deficits in MS patients. In: ACTRIMS-ECTRIMS; 2020 September 11, 2020; Virtual. Penner I. editor Treatment of cognitive deficits in MS patients. In: ACTRIMS-ECTRIMS; 2020 September 11, 2020; Virtual.
159.
go back to reference Quinn É, Hynes SM. Occupational therapy interventions for multiple sclerosis: a scoping review. Scand J Occup Ther. 2020; p. 1-16 Quinn É, Hynes SM. Occupational therapy interventions for multiple sclerosis: a scoping review. Scand J Occup Ther. 2020; p. 1-16
160.
go back to reference Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013;94(7):1360–76.PubMed Blikman LJ, Huisstede BM, Kooijmans H, Stam HJ, Bussmann JB, van Meeteren J. Effectiveness of energy conservation treatment in reducing fatigue in multiple sclerosis: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2013;94(7):1360–76.PubMed
161.
go back to reference Clancy M, Drerup M, Sullivan AB. Outcomes of Cognitive-behavioral treatment for insomnia on insomnia, depression, and fatigue for individuals with multiple sclerosis: a case series. Int J MS Care. 2015;17(6):261–7.PubMedPubMedCentral Clancy M, Drerup M, Sullivan AB. Outcomes of Cognitive-behavioral treatment for insomnia on insomnia, depression, and fatigue for individuals with multiple sclerosis: a case series. Int J MS Care. 2015;17(6):261–7.PubMedPubMedCentral
162.
go back to reference Gromisch ES, Kerns RD, Czlapinski R, Beenken B, Otis J, Lo AC, et al. Cognitive behavioral therapy for the management of multiple sclerosis-related pain: a randomized clinical trial. Int J MS Care. 2020;22(1):8–14.PubMedPubMedCentral Gromisch ES, Kerns RD, Czlapinski R, Beenken B, Otis J, Lo AC, et al. Cognitive behavioral therapy for the management of multiple sclerosis-related pain: a randomized clinical trial. Int J MS Care. 2020;22(1):8–14.PubMedPubMedCentral
163.
go back to reference Ratajska A, Zurawski J, Healy B, Glanz BI. Computerized cognitive behavioral therapy for treatment of depression in multiple sclerosis: a narrative review of current findings and future directions. Int J MS Care. 2019;21(3):113–23.PubMedPubMedCentral Ratajska A, Zurawski J, Healy B, Glanz BI. Computerized cognitive behavioral therapy for treatment of depression in multiple sclerosis: a narrative review of current findings and future directions. Int J MS Care. 2019;21(3):113–23.PubMedPubMedCentral
164.
go back to reference Drulovic J, Kisic-Tepavcevic D, Pekmezovic T. Epidemiology, diagnosis and management of sexual dysfunction in multiple sclerosis. Acta Neurol Belg. 2020. Drulovic J, Kisic-Tepavcevic D, Pekmezovic T. Epidemiology, diagnosis and management of sexual dysfunction in multiple sclerosis. Acta Neurol Belg. 2020.
165.
go back to reference Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med. 2011;78(2):176–91.PubMed Ben-Zacharia AB. Therapeutics for multiple sclerosis symptoms. Mt Sinai J Med. 2011;78(2):176–91.PubMed
166.
go back to reference Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric symptoms of multiple sclerosis: state of the art. Psychiatry Investig. 2019;16(12):877–88.PubMedPubMedCentral Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric symptoms of multiple sclerosis: state of the art. Psychiatry Investig. 2019;16(12):877–88.PubMedPubMedCentral
167.
go back to reference Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275–88.PubMed Phé V, Chartier-Kastler E, Panicker JN. Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275–88.PubMed
168.
go back to reference Guarino AH, Cornell M. Opioids as a treatment option for ms patients with chronic pain. Int J MS Care. 2005;7(1):10–5. Guarino AH, Cornell M. Opioids as a treatment option for ms patients with chronic pain. Int J MS Care. 2005;7(1):10–5.
169.
go back to reference Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.PubMedPubMedCentral Smith RV, Havens JR, Walsh SL. Gabapentin misuse, abuse and diversion: a systematic review. Addiction. 2016;111(7):1160–74.PubMedPubMedCentral
170.
go back to reference Falkowski G. 6 ways to combat pain without using meds. MS Focus Mag. 2016. Falkowski G. 6 ways to combat pain without using meds. MS Focus Mag. 2016.
171.
go back to reference Senders A, Borgatti A, Hanes D, Shinto L. Association between pain and mindfulness in multiple sclerosis: a cross-sectional survey. Int J ms care. 2018;20(1):28–34.PubMedPubMedCentral Senders A, Borgatti A, Hanes D, Shinto L. Association between pain and mindfulness in multiple sclerosis: a cross-sectional survey. Int J ms care. 2018;20(1):28–34.PubMedPubMedCentral
172.
go back to reference Zeidan F, Adler-Neal AL, Wells RE, Stagnaro E, May LM, Eisenach JC, et al. Mindfulness-meditation-based pain relief is not mediated by endogenous opioids. J Neurosci. 2016;36(11):3391–7.PubMedPubMedCentral Zeidan F, Adler-Neal AL, Wells RE, Stagnaro E, May LM, Eisenach JC, et al. Mindfulness-meditation-based pain relief is not mediated by endogenous opioids. J Neurosci. 2016;36(11):3391–7.PubMedPubMedCentral
173.
go back to reference Binns CC. Managing a drug dependency. MS FOCUS Mag. 2020; p. 36–7. Binns CC. Managing a drug dependency. MS FOCUS Mag. 2020; p. 36–7.
177.
go back to reference Salimzadeh Z, Damanabi S, Kalankesh LR, Ferdousi R. Mobile applications for multiple sclerosis: a focus on self-management. Acta Inf Med. 2019;27(1):12–8. Salimzadeh Z, Damanabi S, Kalankesh LR, Ferdousi R. Mobile applications for multiple sclerosis: a focus on self-management. Acta Inf Med. 2019;27(1):12–8.
Metadata
Title
Comprehensive Approach to Management of Multiple Sclerosis: Addressing Invisible Symptoms—A Narrative Review
Authors
Lynsey Lakin
Bryan E. Davis
Cherie C. Binns
Keisha M. Currie
Mary R. Rensel
Publication date
01-06-2021
Publisher
Springer Healthcare
Published in
Neurology and Therapy / Issue 1/2021
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-021-00239-2

Other articles of this Issue 1/2021

Neurology and Therapy 1/2021 Go to the issue